Session III Round
Chairman's Summing Up Chairman Professor R Vanbreuseghem (1) MICONAZOLE -TOLERANCE AND TOXICITY Professor Vanbreseghem (Chairman) raised the question of tolerance and toxicity. In some papers there had been little complaint about the tolerance of miconazole. There was rather more in other papers, and one problem came back regularly: that of diarrhoea, termed by some investigators 'late diarrheea'. With the use of the intravenous route there had been a complaint of venous thrombosis, which did not seem to be very important. He asked for comments on these two points.
Dr H B Levine (Oakland) said that his experience had been only in animals, with some tangential experience obtained while working with physicians. It seemed to him that phlebitis was not considered much of a problem after the reformulation of miconazole. And he did not recall, going through the cases that Dr Stevens and he had studied, that diarrhoea was a very significant problem either. He had been surprised to learn of it.
In the animal model they had employed an unsatisfactory route for the use of miconazole. They had deposited this relatively insoluble drug intramuscularly. There was a severe irritant effect, with necrotic lesions, which they understood and anticipated in advance of their work. The work involved developing a model rather than developing a route of administration, in particular for acute rather than for chronic coccidioidomycosis.
Professor Vanbreuseghem (Chairman) asked whether anyone from Janssen Pharmaceutica could explain the difference between the two intravenous solutions, the later one being the better tolerated.
Dr A Reyntjens (Beerse) suggested that the formulation producing the irritation had contained a certain number of buffers, such as citric acid. These had later been withdrawn though retaining a stable formulation. The reason for the improvement had been this withdrawal of the buffers. Dr H B Levine (Oakland) said he understood the vehicle was a polyethoxylated castor oil containing an acetate buffering system with a slightly acid pH. When the buffer system had been removed it was found that the product did not in fact deteriorate, and all adverse effects due to the cremophor vehicle disappeared. But he agreed with Dr Reyntjens that this polyethoxylated component was not the compound that caused the irritation, and the latter reiterated that it was a question of buffers.
Professor K rn (Wuelfrauth) asked what was known about the clinical toxicology of the solvent.
Dr A Reyntiens (Beerse) said they had not made separate studies of the clinical toxicity of the solvent, but this type of solvent had been used with a certain number of other therapeutic compounds and had never been observed to show clinical toxicity, even at higher concentrations and with more frequent and prolonged use. It had been suggested, although without any proof in man, that the compound might sometimes produce an allergic reaction. In dogs this solvent could produce some increase of histamine, but it had never been seen to do so in human beings, a conclusion with which Dr Paul Janssen agreed.
Professor Vanbreuseghem (Chairman) then turned to the question of diarrhoea induced by oral miconazole. What caused it and what was the best treatment for this diarrhoea? He assumed that miconazole will be used more and more by mouth and they would have to be prepared to counteract this problem.
Dr H Brincker (Odense) said they too had noticed diarrhoea in patients receiving oral tablets. He thought it may be due to an alteration of the bacterial flora of the colon. They had given these patients cultures of Lactobacillus bulgaricus to prevent it, and their impression, although he had no proof, was that this removed some of the problems.
When the Chairman asked what kind of alteration was seen in the microflora, Dr Brincker said that they had not actually investigated it. But he gave these cultures in order to prevent this diarrhoea, and his impression was that it had a good effect.
Professor Vanbreuseghem (Chairman) thought the phenomenon strange, since miconazole was mycostatic. Complaints after antibiotics usually came from the development of candida.
Dr H B Levine (Oakland) emphasized the drug's broader spectrum of activity. It was bacteriostatic, especially against Gram-positive organisms. The Chairman agreed, although not very much was known about that aspect.
Professor W Stille (Frankfurt) asked what was known about the activity of miconazole against anaerobic bacteria. Usually drugs with activity against anaerobes lead to diarrhoea. He suggested that could be the explanation.
Dr J Symoens (Beerse) said that he knew of no data on the activity of miconazole against anaerobes.
Dr J Martinek (Shaffhausen) said that miconazole, as well as diconazole and clotrimazole, had considerable activity against clostridia. Professor Vanbreuseghem (Chairman) then asked what could be said on the treatment of diarrheea.
Dr M J 0 Macedo (Brazil) said that their 5 cases had all been treated with an intestinal adsorbent all with very good results. In only patient did they have to stop the treatment and that patient had already been cured of the mucosal and pulmonary lesions.
Professor Vanbreuseghem (Chairman) then commented on Dr Negroni's observation of a case of sensitization to miconazole with the production of precipitins in the serum. He asked if anybody else had made such an observation.
Professor W Stille (Frankfurt) said that there was the doubtful case which he had presented. Although it had not been proved it looked like an allergic reaction.
A speaker from the floor described a case which was not yet published. After a single intravenous dose of 400 mg of miconazole, one patient developed a major impairment of renal function with oliguria, hyperkaleemia (over 6.8 mEq/1) with metabolic acidosis associated with hypotension, shock and coma. The patient recovered in 24 hours with administration of dopamine, diuretics, and artificial ventilation.
Shortly afterwards they stopped the drug. He supposed that the effects had been due to miconazole because 2 days later they had tried an oral administration and had exactly the same reaction.
He was also concerned about synergy with anticoagulant therapy. They had a case after heart valve replacement, who developed Candida albicans endocarditis. She was given nicumalone and while under miconazole therapy she needed only 2 mg of nicumalone twice a week. After 20 months when the miconazole therapy was stopped, she needed 3 to 4 mg of nicumalone daily. Care must be taken in this situation.
There was a further report from the floor about the coagulation problem. A patient with aspergillus osteomyelitis of the vertebral spine had been receiving miconazole for about 5 months. He received anticoagulant therapy with small quantities of phenprocoumon. Having stopped the phenprocoumon there was still a coagulation defect, with a low factor V and a low prothrombin complex. It therefore seemed that there might be some interference with the coagulation mechanism.
(2) MICONAZOLE -
ROUTE OF ADMINISTRATION
Professor Vanbreuseghem (Chairman) then focused attention on the administration route. Was it better given intravenously or orally, or by other means?
Professor G Velluti (Modena) referring to the lack of published information about intrapleural injection of miconazole, offered his personal observation. There was a possibility of implantation of fungal infections in the pleural cavity as the consequence of fistulization of the lung, or during intrapleural treatment with cortisone and antibiotics. Pleural fungal infection was characterized by hemorrhagic exudate in the cavity. He had treated a case of pleural Aspergillusfumigatus infection (demonstrated by repeated positive cultures) with 20 mg of miconazole intrapleurally. After 3 days the exudate was not hemorrhagic and the culture was negative for fungi. So far there were no definitive results, but the intrapleural injection 20 mg of miconazole diluted in 8 ml of physiological saline, had been very well tolerated.
Professor Vanbreuseghem (Chairman) asked whether the route to be recommended depended on the disease.' Dr H Brincker (Odense) had dealt mostly with leukemia cases, in which it was very important to get a high concentration of miconazole because the drug is fungistatic, not fungicidal, in the concentrations possible in human beings. A fungistatic concentration may not be enough because these patients did not have granulocytes. Successes with chemotherapy of fungus infections in leukemia patients were very rare. He thought that in leukemia cases the intravenous route should be used, because otherwise the concentration will not be as high as possible.
Professor J L Michaux (Louvain) said that prevention is better achieved by oral administration. But if the patient had a fever of unknown origin, intravenous administration was well tolerated with a dose of 1.2-1.5 g daily in four injections, with slow administration.
Professor K Bartmann ( Wuelfrath) asked for some details about intrathecal application.
Dr J Symoens (Beerse) said that the drug had been given intrathecally to 5 patients to date, patients with cryptococcus and coccidioides. In all of them 20 mg (i.e. 2 ml) of the intravenous solution had been given. In some, the intravenous solution was used undiluted; in others it was diluted to 50 % with physiological saline. In one of the patients at least, 16 courses had been given on successive days, one injection every day.
Dr H B Levine (Oakland) said that much of this work had been done by Dr Sung at the Veterans' Administration Hospital in Fresno. Roughly speaking, with a dose of 20 mg, cerebrospinal fluid concentrations of miconazole were biologically determined to be in the magnitude of 7-10 ,ug/ml, persisting through about an 8 to 9hour period. The procedure had been associated with very dramatic results in the coccidioides patients. In one instance where the patient died of another cause, the meninges were free of culturable coccidioides.
Professor Vanbreuseghem (Chairman) felt that in acute mycotic infections the intravenous route was required, but not in all cases. As a prophylactic measure the oral route seemed best and was probably the only one that could be used.
Dr K Citron (London) asked what were the usual blood levels obtained after intravenous and oral administration. Did these change during the course of prolonged daily therapy? Dr J Symoens (Beerse) said that when the same dose was given orally or intravenously, the sole difference was that after intravenous injection there was a very high initial peak which lasted for 2 hours. That peak was approximately 10 times higher than with the same oral dose.
Decay was triphasic. The first phase was very rapid (due to very active metabolism) with a half-life of approximately 15 minutes. The second phase had a half-life of 2 hours and the last phase had a half-life of 24 hours. This third, long phase seemed to be due to very strong protein binding; 90% of the drug is bound to proteins. During repeated and prolonged administration this did not change.
Professor E Drouhet (Paris) declared that blood levels were important, and that the figures given were based on physicochemical methods. The figures that Dr Levine had obtained seemed to show that the drug disappeared after 6-8 hours.
Dr H B Levine (Oakland) replied that their data were in substantial accord with those of Dr Symoens. They had determined approximately 800-1000 plasma levels for miconazole. After intravenous doses of 800-1000 mg, biologically determined levels in excess of 7.5 ,tg/ml of plasma were obtained. There was an initial rapid decline with an asymptotic approach towards zero that lasted for about 6-8 hours, but usually the next dose is given at about that time. The pattern was cyclical. Once levels in excess of 3-4 ug/ml had been obtained, however transiently, a change for the benefit of the patient was apparent.
In the United States they had not yet received approval for oral use and he did not have comparable data for the oral route.
(
3) MICONAZOLE -INDICATIONS FOR USE
Professor Vanbreuseghem (Chairman) said that from what had been said they knew that miconazole was active in candidiasis, in cryptococcosis, in torulopsis infections, in paracoccidioidomycosis, perhaps in aspergillosis and partly in coccidioidomycosis. But he added that there were many other mycotic infections. He asked if everybody agreed with this analysis, and if there were any other suggestions for the use of miconazole.
Dr H B Levine (Oakland) said that their experience with aspergillus had not been good. Admittedly, this had been only in 3 or 4 patients, but they had done sensitivity trials with the cultures obtained from pulmonary aspergillosis with aspergilloma and in each of the 4 instances the minimum inhibitory concentration was in excess of 6 mg/mi. Professor W Stille (Frankfurt) said that aspergilloma was not a problem of intravenous or systemic chemotherapy. If there was chemotherapy for aspergilloma it could only be by local instillation. The mycotic agent had to be deposited by catheter into the right place. One could never reach aspergilloma with intravenous therapy.
Dr H B Levine (Oakland) admitted that this was true although, in his experience, the sensitivity of aspergillus species to miconazole was quite low.
Despite possible sources of error in the determination of minimal inhibitory concentrations (MIC) he said that in circumstances where, with a susceptible organism like coccidioides, the MIC was approximately 1 ,tg/ml or less, in virtually identical circumstances, in the same media and under comparable conditions of culture and inocula, it was 6-12 times higher for aspergillus.
Dr Heltberg (Vi/le) wondered if candida could develop higher levels of resistance, so that there might be problems, for example, in a department where it was used prophylactically.
Mr J Van Cutsem (Beerse) confirmed that the fungus remains stable; its sensitivity does not change and the MIC is constant.
Professor E Drouhet (Paris) described the use of miconazole intravenously, locally on the face and in subcutaneous tissues, in a case of ficomycosis produced by Antomoftera coronata. During 2 years amphotericin B, 5-fluorocytosine potassium iodide and salicylic acid preparation for oral use, had little effect. Miconazole was therefore tried.
A 23-year-old Cameroon subject had a very large tumour of the face and it was necessary to insert cannule so that he could breathe. After he had been treated with miconazole intravenously and locally his eosinophilia rose from 6-35 %. So the evolution was stopped but there was no cure, and they had been obliged to stop the treatment.
His purpose was to emphasize that Antomoftera coronata which was sensitive to 6 ,ug of miconazole could not be cured by intravenous and local miconazole, but nor could it be cured by other drugs. This emphasized the need to develop more antifungal agents if some remaining difficult mycoses are to be cured.
Professor Usco discussed the significance that had to be given to the finding of Candida albicans at bile culture examination.
This condition was sometimes but not always associated with the clinical signs and symptoms of acute or subacute cholangitis. He wondered whether a candidal cholangitis did exist and consequently if it had to be treated when suspected. From the slides which had been shown by Dr Symoens that morning, where biliary candidosis was not mentioned, the answer appeared to be negative. This was also the opinion of his own study group, but many people still talked about candidal cholangitis.
Their own experience was based on observation of 8 cases with positive bile cultures for Candida albicans. In 6 of them candida was associated with bacterial pathogenic flora and a clinical picture of cholangitis was also present. The other 2 cases, positive only for candida, were asymptomatic. All strains were always pathogenic when given intravenously to rabbits.
They had treated these patients with antibacterial antibiotics and/or an antimycotic, not miconazole but 5-fluorocytosine. Only in patients with negative bacterial bile cultures did the symptoms disappear. On the other hand, no influence on the clinical picture of cholangitis was observed in 5 of the 6 patients in which the bile became negative for candida. It therefore seemed that the finding of Candida albicans in the bile did not as a rule signify candidal cholangitis.
Professor Vanbreuseghem (Chairman) also did not personally believe that this type of infection by candida had been demonstrated so far. Professor C P A Van Boven (Maastrich) asked if there were any contra-indications to the use of miconazole, such as hepatic dysfunction.
Dr J Symoens (Beerse) said that miconazole had been tested in approximately 20 intensive-care patients in a study in Bruges. Several were suffering from serious hepatic conditions and the drug had not induced toxicity in any of them.
